Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Series B | Dead

Total Raised


Last Raised


About Cytomics Pharmaceuticals

Developer of therapeutics based on protein turnover-controlling molecules. The company develops drugs based on a screening technology designed to identify molecules targeting the Ubiquitin-proteasome protein degradation pathway. The company's technology has potential applications in the treatment of inflammatory diseases, cancer, and nosocomial fungal infections.

Cytomics Pharmaceuticals Headquarter Location

86 rue de Paris Batiment Meleze

Orsay, 91400,


33 1 69 18 72 12

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.